Oncotarget

Research Papers:

Galectin-3 acts as an angiogenic switch to induce tumor angiogenesis via Jagged-1/Notch activation

Sofia Nascimento dos Santos, Helen Sheldon, Jonathas Xavier Pereira, Christopher Paluch, Esther M. Bridges, Márcia Curry El-Cheikh, Adrian L. Harris and Emerson Soares Bernardes _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:49484-49501. https://doi.org/10.18632/oncotarget.17718

Metrics: PDF 2507 views  |   HTML 7470 views  |   ?  


Abstract

Sofia Nascimento dos Santos1, Helen Sheldon2, Jonathas Xavier Pereira3, Christopher Paluch4, Esther M Bridges2, Márcia Curry El-Cheikh5, Adrian L Harris2 and Emerson Soares Bernardes1

1Radiopharmacy Department, Nuclear Energy Research Institute, São Paulo, Brazil

2Department of Medical Oncology, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK

3Department of Pathology, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

4T-cell Biology Group, Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK

5Institute for Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

Correspondence to:

Emerson Soares Bernardes, email: [email protected]

Keywords: angiogenesis, cancer, galectin-3, Jagged-1, Notch

Received: March 09, 2016     Accepted: April 25, 2017     Published: May 09, 2017

ABSTRACT

Angiogenesis is a coordinated process tightly regulated by the balance between Delta-like-4 (DLL4) and Jagged-1 (JAG1) in endothelial cells. Here we show that galectin-3 (gal-3), a glycan-binding protein secreted by cancer cells under hypoxic conditions, triggers sprouting angiogenesis, assisted by hypoxic changes in the glycosylation status of endothelial cells that enhance binding to gal-3. Galectin-3’s proangiogenic functions were found to be predominantly dependent on the Notch ligand JAG1. Differential direct binding to JAG1 was shown by surface plasmon resonance assay. Upon binding to Notch ligands, gal-3 preferentially increased JAG1 protein half-life over DLL4 and preferentially activated JAG1/Notch-1 signaling in endothelial cells. JAG1 overexpression in Lewis lung carcinoma cells accelerated tumor growth in vivo, but this effect was prevented in Lgals3−/− mice. Our findings establish gal-3 as a molecular regulator of the JAG1/Notch-1 signaling pathway and have direct implications for the development of strategies aimed at controlling tumor angiogenesis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17718